296 related articles for article (PubMed ID: 24712744)
1. New affinity probe targeting VEGF receptors for kinase inhibitor selectivity profiling by chemical proteomics.
Ku X; Heinzlmeir S; Helm D; Médard G; Kuster B
J Proteome Res; 2014 May; 13(5):2445-52. PubMed ID: 24712744
[TBL] [Abstract][Full Text] [Related]
2. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
3. A new chemical probe for quantitative proteomic profiling of fibroblast growth factor receptor and its inhibitors.
Ku X; Heinzlmeir S; Liu X; Médard G; Kuster B
J Proteomics; 2014 Jan; 96():44-55. PubMed ID: 24184958
[TBL] [Abstract][Full Text] [Related]
4. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
Verkhivker GM
Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
[TBL] [Abstract][Full Text] [Related]
5. A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor.
Li F; Jiang S; Zu Y; Lee DY; Li Z
J Nucl Med; 2014 Sep; 55(9):1525-31. PubMed ID: 24970912
[TBL] [Abstract][Full Text] [Related]
6. Characterization of a chemical affinity probe targeting Akt kinases.
Pachl F; Plattner P; Ruprecht B; Médard G; Sewald N; Kuster B
J Proteome Res; 2013 Aug; 12(8):3792-800. PubMed ID: 23795919
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.
Harris PA; Boloor A; Cheung M; Kumar R; Crosby RM; Davis-Ward RG; Epperly AH; Hinkle KW; Hunter RN; Johnson JH; Knick VB; Laudeman CP; Luttrell DK; Mook RA; Nolte RT; Rudolph SK; Szewczyk JR; Truesdale AT; Veal JM; Wang L; Stafford JA
J Med Chem; 2008 Aug; 51(15):4632-40. PubMed ID: 18620382
[TBL] [Abstract][Full Text] [Related]
8. Quantitative proteomics of kinase inhibitor targets and mechanisms.
Daub H
ACS Chem Biol; 2015 Jan; 10(1):201-12. PubMed ID: 25474541
[TBL] [Abstract][Full Text] [Related]
9. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
Hess-Stumpp H; Haberey M; Thierauch KH
Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
[TBL] [Abstract][Full Text] [Related]
11. Proteome-wide discovery of unknown ATP-binding proteins and kinase inhibitor target proteins using an ATP probe.
Adachi J; Kishida M; Watanabe S; Hashimoto Y; Fukamizu K; Tomonaga T
J Proteome Res; 2014 Dec; 13(12):5461-70. PubMed ID: 25230287
[TBL] [Abstract][Full Text] [Related]
12. Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes.
Shi H; Zhang CJ; Chen GY; Yao SQ
J Am Chem Soc; 2012 Feb; 134(6):3001-14. PubMed ID: 22242683
[TBL] [Abstract][Full Text] [Related]
13. Discovery of tyrosine kinase inhibitors by docking into an inactive kinase conformation generated by molecular dynamics.
Zhao H; Huang D; Caflisch A
ChemMedChem; 2012 Nov; 7(11):1983-90. PubMed ID: 22976951
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.
Smith BJ; Pithavala Y; Bu HZ; Kang P; Hee B; Deese AJ; Pool WF; Klamerus KJ; Wu EY; Dalvie DK
Drug Metab Dispos; 2014 May; 42(5):918-31. PubMed ID: 24608633
[TBL] [Abstract][Full Text] [Related]
15. Optimized chemical proteomics assay for kinase inhibitor profiling.
Médard G; Pachl F; Ruprecht B; Klaeger S; Heinzlmeir S; Helm D; Qiao H; Ku X; Wilhelm M; Kuehne T; Wu Z; Dittmann A; Hopf C; Kramer K; Kuster B
J Proteome Res; 2015 Mar; 14(3):1574-86. PubMed ID: 25660469
[TBL] [Abstract][Full Text] [Related]
16. Chemical proteomic analysis reveals alternative modes of action for pyrido[2,3-d]pyrimidine kinase inhibitors.
Wissing J; Godl K; Brehmer D; Blencke S; Weber M; Habenberger P; Stein-Gerlach M; Missio A; Cotten M; Müller S; Daub H
Mol Cell Proteomics; 2004 Dec; 3(12):1181-93. PubMed ID: 15475568
[TBL] [Abstract][Full Text] [Related]
17. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
18. A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase.
Zuo Y; Shi Y; Li X; Teng Y; Pan Z
Sci Rep; 2015 Nov; 5():16136. PubMed ID: 26531233
[TBL] [Abstract][Full Text] [Related]
19. Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism.
Iwata H; Imamura S; Hori A; Hixon MS; Kimura H; Miki H
Biochemistry; 2011 Feb; 50(5):738-51. PubMed ID: 21182308
[TBL] [Abstract][Full Text] [Related]
20. Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases.
Song J; Yoo J; Kwon A; Kim D; Nguyen HK; Lee BY; Suh W; Min KH
PLoS One; 2015; 10(9):e0138823. PubMed ID: 26401847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
